Jade Biosciences, Inc. JBIO
Set alert
As of Nov 2, 11:18 AM ET
- YTD
- -11.02%
- 1 year
- +40.10%
- Open
- 14.44
- Prev close
- 14.06
- Mkt cap
- 873.83M
- Vol
- 114.47K
- Avg vol
- 898.85K
- EPS
- -1.92
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 13.55
- High
- 14.44
- Forward P/E
- -6.29
- Beta
- 0.00
- Short ratio
- 12.92
- Inst. own
- 116.01%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 12, 2026
- 50-d avg
- 20.55
- 200-d avg
- 18.29
- 1y target
- 50.13
News
-
6 days ago benzinga.com
BTIG Reiterates Buy on Jade Biosciences, Maintains $77 Price Target
BTIG analyst Julian Harrison reiterates Jade Biosciences (NASDAQ:JBIO) with a Buy and maintains $77 price target.
1 week ago globenewswire.com
Jade Biosciences to Highlight Advancement of JADE101 Development Program at American Society of Nephrology (ASN) Kidney Week 2026
EVERGREEN Phase 3 Trial-in-Progress poster presents planned study design of JADE101 in IgA nephropathy; initiation now expected in the fourth quarter of 2026 JUNIPER Phase 2 Trial-in-Progress poster…
-
1 month ago benzinga.com
Wedbush Reiterates Outperform on Jade Biosciences, Maintains $47 Price Target
Wedbush analyst Laura Chico reiterates Jade Biosciences (NASDAQ:JBIO) with a Outperform and maintains $47 price target.
-
1 month ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Jade Biosciences, Maintains $55 Price Target
HC Wainwright & Co. analyst Arthur He reiterates Jade Biosciences (NASDAQ:JBIO) with a Buy and maintains $55 price target.
1 month ago seekingalpha.com
Jade Biosciences, Inc. (JBIO) Discusses JADE301 Program Profile and Preclinical Data in Dermatomyositis Transcript
Jade Biosciences, Inc. (JBIO) Discusses JADE301 Program Profile and Preclinical Data in Dermatomyositis Transcript
1 month ago globenewswire.com
Jade Biosciences Announces Preclinical Data Characterizing JADE301, a Potentially Best-in-Class, Half-Life-Extended Anti-IFN-β Monoclonal Antibody in Development for Dermatomyositis, at EADV 2026
JADE301 is designed to build on a clinically validated IFN-β mechanism with a differentiated profile designed for infrequent subcutaneous dosing JADE301 demonstrated high-affinity, selective IFN-β…
1 month ago defenseworld.net
Jade Biosciences, Inc. (NASDAQ:JBIO) Stock Has Average Target Price of $51.75 According to Brokerages
Jade Biosciences, Inc. (NASDAQ: JBIO - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the ten research firms that are presently covering the firm, MarketBeat reports.…
1 month ago seekingalpha.com
Jade Biosciences, Inc. (JBIO) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Jade Biosciences, Inc. (JBIO) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
2 months ago globenewswire.com
Jade Biosciences to Participate in Upcoming Conferences
SAN FRANCISCO and VANCOUVER, British Columbia, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on…
2 months ago seekingalpha.com
Jade Biosciences: Duration Is The Real Product
Jade Biosciences (JBIO) targets IgAN with JADE101, aiming for quarterly dosing that could significantly improve patient adherence versus competitors' more frequent regimens. Phase 1 data show JADE101…
-
2 months ago benzinga.com
Wedbush Maintains Outperform on Jade Biosciences, Raises Price Target to $47
Wedbush analyst Laura Chico maintains Jade Biosciences (NASDAQ:JBIO) with a Outperform and raises the price target from $45 to $47.
-
2 months ago benzinga.com
Jade Biosciences Q2 EPS $(0.76) Misses $(0.64) Estimate
Jade Biosciences (NASDAQ:JBIO) reported quarterly losses of $(0.76) per share which missed the analyst consensus estimate of $(0.64) by 18.75 percent. This is a 11.63 percent increase over losses of…
2 months ago globenewswire.com
Jade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Announced positive interim Phase 1 results for JADE101 demonstrating potential for every 12-week subcutaneous dosing and best-in-class clinical activity in IgA nephropathy Phase 2 JADE101 clinical…
4 months ago globenewswire.com
Jade Biosciences Announces Appointment of Mark Eisner, M.D., M.P.H., to Board of Directors
SAN FRANCISCO and VANCOUVER, British Columbia, June 26, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (the “Company” or “Jade”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on…
4 months ago globenewswire.com
Jade Biosciences Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
SAN FRANCISCO and VANCOUVER, British Columbia, June 05, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on…
5 months ago benzinga.com
Stock Market Today: S&P 500, Dow, Nasdaq Futures Fall As House Challenges Trump's Military Authority— Broadcom, CrowdStrike In Focus (UPDATED)
(Editor’s note: The future prices of benchmark tracking ETFs and the headline were updated in the story.) U.S. stock futures declined on Thursday after a lower close on Wednesday, as the Nasdaq 100,…
5 months ago benzinga.com
Ciena, Docusign And 3 Stocks To Watch Heading Into Thursday
Stocks to watch: CIEN, DOCU, LULU, report earnings today. MRAAF introduces world's first 100Vdc 2.2μF chip MLCC for auto safety.
5 months ago globenewswire.com
Jade Biosciences Announces Pricing of Public Offering of Common Stock
SAN FRANCISCO and VANCOUVER, British Columbia, June 03, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. ("Jade" or the "Company") (Nasdaq: JBIO), a clinical-stage biotechnology company focused on…
5 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
5 months ago globenewswire.com
Jade Biosciences Announces Proposed Underwritten Public Offering
SAN FRANCISCO and VANCOUVER, British Columbia, June 03, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on…
5 months ago marketbeat.com
Jade Biosciences' JADE101 Delivers Deep IgA Cuts, Clearing Path for Kidney Trials
Jade Biosciences NASDAQ: JBIO said interim results from a Phase 1 healthy volunteer study of JADE101 showed rapid and durable reductions in serum IgA, supporting the company's plan to advance the…
5 months ago seekingalpha.com
Jade Biosciences, Inc. (JBIO) Discusses Positive Interim Results From JADE101 Phase I Healthy Volunteer Study and Development Plans Transcript
Jade Biosciences, Inc. (JBIO) Discusses Positive Interim Results From JADE101 Phase I Healthy Volunteer Study and Development Plans Transcript
5 months ago benzinga.com
Why Is Jade Biosciences Stock Trading Lower On Monday?
Jade Biosciences, Inc. (NASDAQ:JBIO) reported interim Phase 1 results for JADE101 in immunoglobulin A nephropathy (IgAN), showing substantial and sustained reductions in immunoglobulin A (IgA), a…
5 months ago benzinga.com
Taylor Morrison Home Surges On Berkshire Hathaway Acquisition, Joins Elmet Group And Other Big Stocks Moving Higher In Monday's Session
U.S. stock futures up, Nasdaq surges 0.35%, with Taylor Morrison's buyout announcement. Other pre-market gainers include ELMT, PURR, and SPCE.
5 months ago globenewswire.com
Jade Biosciences Announces Positive Interim Phase 1 Results for JADE101 Demonstrating Potential Best-in-Class Profile and Every-12-Week Dosing in IgA Nephropathy
SAN FRANCISCO and VANCOUVER, British Columbia, June 01, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (the “Company” or “Jade”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on…
5 months ago globenewswire.com
Jade Biosciences to Host Conference Call and Webcast on June 1, 2026, at 8:00 a.m. ET to Discuss Interim Phase 1 Healthy Volunteer Results for JADE101, a Novel, Potentially Best-in-Class Anti-APRIL Monoclonal Antibody in Development for IgA Nephropathy
SAN FRANCISCO and VANCOUVER, British Columbia, May 29, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (the “Company” or “Jade”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on…
5 months ago globenewswire.com
Jade Biosciences Announces First Participant Dosed in First-in-Human Phase 1 Clinical Trial of JADE201, a Novel Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody
Interim Phase 1 data in rheumatoid arthritis expected in 2027 are anticipated to inform indication prioritization across multiple potential autoimmune indications supported by BAFF-R biology JADE201…
6 months ago benzinga.com
XOMA Royalty, Oruka Therapeutics, Repay Holdings And Other Big Stocks Moving Higher On Monday
U.S. stocks were lower, Dow Jones fell 0.1% on Monday. XOMA shares rose on Ligand's plans to acquire XOMA for $39.00/share. Other big gainers: MANE, ORKA, OGN, XE, PLBL, SLS, ANAB, EVH, IHRT, RPAY,…
7 months ago benzinga.com
Micron To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Monday
Top analysts updated ratings for MU, EPAM, WLTH, OKUR, BLDR, DMRC, JBIO, CRCL. See changes and ratings on analyst ratings page.
9 months ago benzinga.com
This Applied Digital Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday
This Applied Digital Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday
10 months ago benzinga.com
Why Intelligent Bio Solutions Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Why Intelligent Bio Solutions Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Friday's Mid-Day Session
-
11 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Friday's Intraday Session
11 months ago benzinga.com
Jazz Pharmaceuticals, Sigma Lithium, Zymeworks And Other Big Stocks Moving Higher On Monday
Jazz Pharmaceuticals, Sigma Lithium, Zymeworks And Other Big Stocks Moving Higher On Monday
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
12 Health Care Stocks Moving In Thursday's Pre-Market Session
1 year ago benzinga.com
Why Sarepta Therapeutics Shares Are Trading Higher By 34%; Here Are 20 Stocks Moving Premarket
Why Sarepta Therapeutics Shares Are Trading Higher By 34%; Here Are 20 Stocks Moving Premarket
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
12 Health Care Stocks Moving In Monday's Pre-Market Session
1 year ago benzinga.com
Expedia, Wolfspeed, HubSpot And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Expedia, Wolfspeed, HubSpot And Other Big Stocks Moving Lower In Friday's Pre-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
1 year ago benzinga.com
Why Pinterest Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket
Why Pinterest Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket